• ,

    Louisiana Lupus Foundation continues to support people living with lupus through COVID fears

    The Louisiana Lupus Foundation invites everyone living with lupus in the state to participate in a needs survey and virtual support group. The needs survey, which is confidential, is available online at www.louisianalupusfoundation.org/survey or at https://forms.gle/zoS1gf2v7L3hqjK39.

    Results will be used to adjust programs and levels of support to people living with lupus as the community prevents the spread of COVID19. Surveys should be completed before the virtual support group meeting on Saturday, April 25 at 12:30pm. The meeting will be conducted through Zoom.com in meeting ID 745-171-568.

    LLF is a charitable, nonprofit focused on supporting people impacted by lupus, an chronic, incurable autoimmune disease.  The local organization as well as lupus groups around the world are working to ensure lupus patients can continue to have access to hydroxychloroquine, a critical medication that they need which have been delayed due to it being prescribed for COVID patients. The novel coronavirus can have a deadly impact on these patients whose bodies are already under attack.

    The support group meets monthly and anyone living with lupus are encouraged to attend.

    ONLINE: Www.louisianalupusfoundation.org

    Read more »
  • ,,

    Doctor explains use of RA, lupus drug to treat coronavirus

    Dr. Rosalind Ramsey Goldman, research professor at Northwestern Medical in Chicag, has written the following article in response to published reports like the one on Newsweek here.

    There are no studies that have looked at whether or not using hydroxychloroquine will prevent the infection with the COVID-19 virus. However, doctors are recommending that patients continue their medications for their rheumatic diseases, and this includes hydroxychloroquine for patients with lupus. If patients become symptomatic and they are worried about this or other infections, they should seek guidance from their rheumatologists and/or other treating physicians.

    Because there is a biologic basis for considering the use of an anti-malarial such as hydroxychloroquine, in the treatment of COVID-19, this drug was tried in France in hospitalized patients to see if the virus was cleared faster than those who did not receive this treatment. In addition, some patients also received an antibiotic. Patients treated with either hydroxychloroquine alone or with antibiotic did clear the infection faster than those who did not receive these medications. This was a very small study, both patients and physicians knew what they were getting because this was an open label study, and this study has yet to be peer reviewed by scientific journals. Therefore, one would ideally want more information before this is an accepted treatment. There is some confusion over whether or not the FDA has approved hydroxychloroquine for COVID-19 so this too needs to be confirmed.

    Since hydroxychloroquine has been used for many years, its safety profile is well known, as opposed to experimental medications with limited use in humans or with those medication used for other conditions. This information from France is encouraging, but it needs to be studied further. This is one of the treatments being used in the US and there are disease registries being set up to get as much information as possible to understand the role of hydroxychloroquine in the treatment of COVID-19.

    For patients with lupus, they should continue their medication, but there may be difficulties getting long term or even new prescriptions filled. There are plans to work together with multiple advocacy groups supporting patients with rheumatic diseases such as lupus to ensure that our patients get the medications they need for their underlying disease while also working with those who are treating patients with the current COVID-19 infection. This is an unprecedented time where stakeholders are collaborating world-wide to control and treat this new viral infection.

    Dr. Rosalind Ramsey-Goldman, MD is a rheumatology specialist in Chicago, IL and has been practicing for 34 years. She specializes in rheumatology.

    Read more »
Back to Top
Facebook Auto Publish Powered By : XYZScripts.com